Ultimovacs Asa Stock Current Valuation
| ULTI Stock | NOK 1.97 0.07 3.43% |
Valuation analysis of Ultimovacs ASA helps investors to measure Ultimovacs ASA's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Ultimovacs ASA's price fluctuation is very risky at this time. Calculation of the real value of Ultimovacs ASA is based on 3 months time horizon. Increasing Ultimovacs ASA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Ultimovacs stock is determined by what a typical buyer is willing to pay for full or partial control of Ultimovacs ASA. Since Ultimovacs ASA is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ultimovacs Stock. However, Ultimovacs ASA's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.97 | Real 1.93 | Hype 1.97 | Naive 2.02 |
The intrinsic value of Ultimovacs ASA's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Ultimovacs ASA's stock price.
Estimating the potential upside or downside of Ultimovacs ASA helps investors to forecast how Ultimovacs stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ultimovacs ASA more accurately as focusing exclusively on Ultimovacs ASA's fundamentals will not take into account other important factors: Ultimovacs ASA Company Current Valuation Analysis
Ultimovacs ASA's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Ultimovacs ASA Current Valuation | 3.35 B |
Most of Ultimovacs ASA's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ultimovacs ASA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Ultimovacs ASA has a Current Valuation of 3.35 B. This is 76.69% lower than that of the Healthcare sector and 27.92% lower than that of the Biotechnology industry. The current valuation for all Norway stocks is 79.86% higher than that of the company.
Ultimovacs Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ultimovacs ASA's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ultimovacs ASA could also be used in its relative valuation, which is a method of valuing Ultimovacs ASA by comparing valuation metrics of similar companies.Ultimovacs ASA is currently under evaluation in current valuation category among its peers.
Ultimovacs Fundamentals
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | 3.35 B | |||
| Shares Outstanding | 34.4 M | |||
| Shares Owned By Insiders | 48.41 % | |||
| Shares Owned By Institutions | 24.83 % | |||
| Price To Book | 7.44 X | |||
| EBITDA | (161.69 M) | |||
| Net Income | (164.72 M) | |||
| Cash And Equivalents | 1.85 M | |||
| Cash Per Share | 11.95 X | |||
| Total Debt | 457 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 12.47 X | |||
| Book Value Per Share | 14.97 X | |||
| Cash Flow From Operations | (125.83 M) | |||
| Earnings Per Share | (5.09) X | |||
| Target Price | 165.0 | |||
| Number Of Employees | 23 | |||
| Beta | 1.42 | |||
| Market Capitalization | 4.11 B | |||
| Total Asset | 655.54 M | |||
| Net Asset | 655.54 M |
About Ultimovacs ASA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ultimovacs ASA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ultimovacs ASA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ultimovacs ASA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.